【ASCO-GU 2025】四川大学华西医院首战告捷
本帖最后由 NatureBoy 于 2025-1-9 17:53 编辑2025年美国临床肿瘤学会-泌尿生殖系统癌症研讨会（ASCO-GU 2025）摘要标题公布，初步统计了下，可能稍有误差，牵头入选成果数
川大华西医院 25项
中山大学系统 8项（肿瘤医院6项、第一医院1项、孙逸仙医院1项）
北京大学系统 7项（肿瘤医院5项、第一医院2项）
中国医科院系统 7项（肿瘤医院7项）
上海交大系统 6项（仁济医院5项、瑞金医院1项）
复旦大学系统 5项（肿瘤医院5项）
*大会收录摘要总数886项
厉害！华科有无？ 不流川 发表于 2025-1-9 16:03
厉害！华科有无？
查到有参加3项复旦肿瘤牵头的国内多中心研究 本帖最后由 NatureBoy 于 2025-1-9 16:12 编辑
华西医院泌尿肿瘤近年算是快速回春了，一年期内成绩单
复旦版2023泌尿外科临床专科声誉 并列第2
医科院版2023泌尿外科科技量值 第1
医科院版2019-2023泌尿外科五年期科技量值 第1
ASCO-GU 2024、2025 第1
ASCO 2024泌尿肿瘤相关部分 第1
EAU 2024 第1
ICS 2024 第1
NatureBoy 发表于 2025-1-9 16:07
查到有参加3项复旦肿瘤牵头的国内多中心研究
谢谢！ 在没有肿瘤专科医院的情况下有这成绩很不错:lol 还统计少了，华西医院牵头是25项:L
01.Risk factors of complications after inguinal lymph node dissection in patients with penile cancer.
02.Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor.
03.Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract urothelial carcinoma: A study focusing on temporal heterogeneity.
04.The impact of neoadjuvant therapy on the formation of tertiary lymphatic structures and the distinct prognosis in prostate cancer.
05.Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: Results from a large-scale longitudinal cohort study.
06.Survival impact of concomitant squamous differentiation in upper tract urothelial carcinoma patients receiving adjuvant chemotherapy.
07.Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines.
08.Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis.
09.Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study.
10.Interpretable machine learning for prostate biopsy: Cohort study.
11.Genomic features of prostate cancer patients with and without ductal adenocarcinoma (DA) based on liquid biopsy.
12.Clinicopathological features and prognosis of MED15-TFE3 rearrangement renal cell carcinoma: An updated report.
13.Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).
14.A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).
15.VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy.
16.Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study.
17.Kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: A pilot study combining endoscopic thulium laser ablation with perioperative disitamab vedotin and immune checkpoint inhibitors.
18.Comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of localized high-risk upper tract urothelial carcinoma: A potential paradigm shift.
19.Efficacy of systemic treatments for advanced non-clear cell renal cell carcinoma: A single-arm systematic review and meta-analysis.
20.The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer.
21.Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021.
22.Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis.
23.Assessment of the proficiency of ChatGPT-4o in an image-based robot-assisted radical prostatectomy scenario.
24.The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis.
25.Global and regional burden of kidney cancer: Analysis and future predictions based on GBD data from 1990 to 2021.
本帖最后由 NatureBoy 于 2025-1-9 17:37 编辑
whoknowsname 发表于 2025-1-9 17:01
在没有肿瘤专科医院的情况下有这成绩很不错
泌尿肿瘤赛道算不错，国内牵头成立CUDA-UTUC协作组、CUDA肾上腺高血压外科协作组、CACA-GU少见肾癌协作组等三个协作组，其他赛道还是干不过肿瘤专科医院，兄弟单位们都很强:dizzy: 看年内重离子质子医院投运后，能否发起追赶 NatureBoy 发表于 2025-1-9 17:34
泌尿肿瘤赛道算不错，国内牵头成立CUDA-UTUC协作组、CUDA肾上腺高血压外科协作组、CACA-GU少见肾癌协作组 ...
复旦榜的肿瘤专科声誉排行榜的前十里非肿瘤专科的也只有华西了:lol
whoknowsname 发表于 2025-1-9 17:57
复旦榜的肿瘤专科声誉排行榜的前十里非肿瘤专科的也只有华西了
同期的ASCO GI表现太拉，我都不好意思发，对应的华西医院腹部肿瘤病房发展明显落后了，GI表现最好的应该是中山或者医科院。 NatureBoy 发表于 2025-1-9 18:33
同期的ASCO GI表现太拉，我都不好意思发，对应的华西医院腹部肿瘤病房发展明显落后了，GI表现最好的应该 ...
哦豁？居然不是北肿？ NatureBoy 发表于 2025-1-9 18:33
同期的ASCO GI表现太拉，我都不好意思发，对应的华西医院腹部肿瘤病房发展明显落后了，GI表现最好的应该 ...
不过你们腹部肿瘤科的介入做的挺不错吧 大华西厉害
页:
[1]